Provided by Tiger Trade Technology Pte. Ltd.

CORGI ONTO 2X DAILY ETF

17.59
-0.6264-3.44%
Post-market: 17.54-0.0483-0.27%16:10 EDT
Volume:6K
Turnover:107.95K
Market Cap:967.36K
PE:- -
High:17.60
Open:17.16
Low:16.93
Close:18.21
52wk High:43.14
52wk Low:10.62
Shares:55.00K
Float Shares:55.00K
Volume Ratio:0.82
T/O Rate:11.40%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Company Profile

Company Name:
CORGI ONTO 2X DAILY ETF
Exchange:
CBOE
Establishment Date:
2026
Employees:
- -
Office Location:
425 Bush Street,Suite 500,San Francisco,California,United States
Zip Code:
94108-3726
Fax:
- -
Introduction:
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.